公司人事任命 - ADARx Pharmaceuticals任命Laura Shawver博士为董事会主席 该任命于2025年9月17日生效[1] - Shawver博士拥有25年生物制药行业经验 曾担任多家被收购企业CEO 包括被AbbVie收购的Capstan Therapeutics 被ARS Pharmaceuticals收购的Silverback Therapeutics以及被Sanofi收购的Synthorx[2] - 目前同时担任Adcendo ApS董事会主席 ARS Pharmaceuticals(纳斯达克:SPRY)和Dovetail Therapeutics董事会成员[2] 管理层评价 - 公司总裁兼CEO Zhen Li博士表示 Shawver的战略增长推动能力和创新疗法开发经验正值公司扩大管线规模的关键时期[2] - Shawver博士认为公司处于关键发展节点 多个临床项目正向重要里程碑推进 且拥有丰富的临床前资产管线[2] - Shawver承诺将与管理层紧密合作 指导公司战略增长并持续构建长期价值[2] 公司业务概况 - ADARx为临床后期生物技术公司 专注于开发新一代RNA治疗方法[3] - 公司技术平台可控制特定疾病驱动因子的表达 开发高选择性RNA靶向疗法[3] - 研发管线涵盖补体介导疾病 遗传病 心血管疾病 血栓形成 中枢神经系统疾病和代谢性疾病(肥胖)等领域[3] - 与AbbVie达成合作及许可选择协议 共同开发针对神经科学 免疫学和肿瘤学领域的小干扰RNA(siRNA)疗法[3]

Fourth US Granted Patent Captures Claims for Future Clinical Dose of PRPMELBOURNE, Australia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s “proenzyme composition” patent was received from the US Patent & Trademark Office (USPTO). The patent specifically captures a fu ...

核心观点 - Cingulate公司与Bend Bio Sciences达成CTx-1301的商业供应协议 为FDA批准后的商业化生产做准备 [1][3] - CTx-1301是一种新型多相缓释ADHD治疗药物 采用专有PTR™技术平台 旨在解决现有疗法局限性 [2][6] - ADHD美国患者基数庞大 超过2000万确诊患者 成人ADHD患病率增长速度快于儿童及青少年群体 [5] 商业合作与生产安排 - Bend Bio Sciences成为CTx-1301在美国的独家商业制造商 协议有效期至2028年 [3] - Cingulate承诺在FDA批准后 100%采购Bend生产的CTx-1301美国商业供应量 [3] - 该合作确保生产安全性和运营效率 支持潜在市场进入准备 [3][4] 产品与技术特性 - CTx-1301为右哌甲酯盐酸盐新型缓释片剂 采用PTR™技术实现三次精确定时释放 [6] - 专有Erosion Barrier Layer（EBL）技术控制药物在预定时间释放 无提前释放风险 [7] - 技术授权自BDD Pharma的OralogiK™配方 采用片中含片剂型设计 [8] 市场与患者规模 - 美国ADHD确诊患者超过2000万人 其中成人患者1200万 17岁以下患者超过800万 [5] - 2022年仅53.6%的儿童和青少年ADHD患者接受药物治疗 65-90%患者症状持续至成年期 [5] - 成人ADHD患病率规模及增长速度均超过儿童和青少年群体总和 [5] 公司战略与管线 - Cingulate专注于利用PTR™技术开发下一代药物 改善每日用药负担及治疗效果不佳的疾病 [9] - 除ADHD外 公司正评估将PTR™技术应用于焦虑症等其他治疗领域 [8][9] - Bend Bio Sciences由三家专业CDMO合并成立 提供小分子能力及释放技术优化服务 [10]

PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at the Lytham Partners Fall 2025 Virtual Investor Conference on September 30, 2025. Additionally, management will be participating in the upcoming 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. Lytham Partners Fall 2025 Investor Conference, September 30 ...

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent’s new Orion® artificial vision system, developed to treat blindness caused by common conditions, has successfully completed a 6-year Early Feasibility Study Cortigent is developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysi ...

NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place from September 27 to October 1, 2025, in San Francisco, CA. The oral presentation will feature data f ...

公司战略举措 - 公司任命CORE IR负责投资者关系与沟通计划 旨在提升投资者认知度 加强股东互动并扩大对机构和零售受众的覆盖范围 [1] - 合作内容包括战略信息传递 非交易路演支持 投资者定向拓展以及沟通项目支持 [2] 管理层表态 - 公司CEO表示此次合作体现对驱动利益相关者价值的持续承诺 并强调将通过市场能见度提升更好地向现有和潜在股东传达价值主张 [2] - CORE IR总裁认可公司在乳腺癌防治领域的创新科学疗法 并表示将协助扩大投资界参与度 [3] 公司业务背景 - 公司为临床阶段生物制药企业 专注于通过创新科学改变乳腺癌治疗方案 [3] - 核心候选药物(Z)-endoxifen为高效SERM/D药物 涵盖乳腺癌风险降低 新辅助治疗 辅助治疗及转移治疗等多个场景 [3]

TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that its CEO, Thomas Jensen, has been invited to present at the upcoming Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global. In addition to his presentation, Mr. Jensen will be interviewed by Oxford Global ...

Peer-reviewed publication highlights potential breakthrough anti-fibrotic properties of LTI-03 in lung tissue from IPF patientsAUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the publication of novel data on its lead drug candidate, LTI-03, in iScience, a peer-reviewed, open-acc ...

AUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the publication of novel data on its lead drug candidate, LTI-03, in iScience, a peer-reviewed, open-access journal published by Cell Press. The paper, titled “LTI-03 peptide demonstrates anti-fibrotic activity in ex vivo lung slic ...